Table 2.

Characteristics of the four included studies

Study	Design	Number of cases	Intervention	Interclass equilibration	Outcomes
Rapid BP reduction trial	A prospective, single-center, randomized, single-blinded study	42	Standard treatment: MAP 110–130 mmHg; Aggressive BP lowering: MAP <110 mmHg	Good	A clinical decline (NIHSS drop ≥2 points) within 48 h; HE rates at 24 h
INTERACT1	A prospective randomized, parallel assignment, safety, efficacy study, open-label study	404	Intensive therapy: BP ≤140 mmHg within 1 h of randomization Control: BP ≤180 mmHg	Good	Intensive BP goals maintained for 24 h safety and tolerability achieved
INTERACT2	A prospective, randomized, open-label, assessor-blinded end-point multicenter, trial	2839	Intensive therapy: BP ≤140 mmHg within 1 h of randomization Control: BP ≤180 mmHg	Good	Death and dependency physical function on the mRS; hematoma volume
ADAPT	A multi-center randomized open-label, blinded end-point trial	75	Target: SBP <150 mmHg or SBP <180 mmHg	Good	Neurological examinations; hematoma and perihematomal edema volumes; the relative CBF within the perihematomal region

ADAPT: Acutely Decreasing Arterial Pressure Trial; INTERACT: Intensive blood pressure reduction in acute cerebral hemorrhage trial; MAP: Mean artery pressure; SBP: Systolic blood pressure; CBF: Cerebral blood flow; BP: Blood pressure; HE: Hematoma enlargement; NIHSS: National institutes of health stroke scale; mRS: Modified rankin scale.